S&P 500   4,350.02 (+0.46%)
DOW   34,111.68 (+0.12%)
QQQ   360.77 (+0.81%)
AAPL   175.69 (+1.01%)
MSFT   320.05 (+0.16%)
META   304.90 (+3.10%)
GOOGL   131.78 (+1.03%)
AMZN   131.25 (+1.48%)
TSLA   254.40 (-0.51%)
NVDA   417.05 (+1.68%)
NIO   8.65 (+2.37%)
BABA   88.61 (+5.35%)
AMD   97.74 (+1.70%)
T   15.16 (-0.98%)
F   12.63 (+3.52%)
MU   69.22 (+1.94%)
CGC   0.85 (+10.14%)
GE   113.12 (+0.12%)
DIS   82.47 (-0.31%)
AMC   7.87 (+2.21%)
PFE   32.57 (-0.85%)
PYPL   58.97 (+0.60%)
NFLX   383.88 (-0.07%)
S&P 500   4,350.02 (+0.46%)
DOW   34,111.68 (+0.12%)
QQQ   360.77 (+0.81%)
AAPL   175.69 (+1.01%)
MSFT   320.05 (+0.16%)
META   304.90 (+3.10%)
GOOGL   131.78 (+1.03%)
AMZN   131.25 (+1.48%)
TSLA   254.40 (-0.51%)
NVDA   417.05 (+1.68%)
NIO   8.65 (+2.37%)
BABA   88.61 (+5.35%)
AMD   97.74 (+1.70%)
T   15.16 (-0.98%)
F   12.63 (+3.52%)
MU   69.22 (+1.94%)
CGC   0.85 (+10.14%)
GE   113.12 (+0.12%)
DIS   82.47 (-0.31%)
AMC   7.87 (+2.21%)
PFE   32.57 (-0.85%)
PYPL   58.97 (+0.60%)
NFLX   383.88 (-0.07%)
S&P 500   4,350.02 (+0.46%)
DOW   34,111.68 (+0.12%)
QQQ   360.77 (+0.81%)
AAPL   175.69 (+1.01%)
MSFT   320.05 (+0.16%)
META   304.90 (+3.10%)
GOOGL   131.78 (+1.03%)
AMZN   131.25 (+1.48%)
TSLA   254.40 (-0.51%)
NVDA   417.05 (+1.68%)
NIO   8.65 (+2.37%)
BABA   88.61 (+5.35%)
AMD   97.74 (+1.70%)
T   15.16 (-0.98%)
F   12.63 (+3.52%)
MU   69.22 (+1.94%)
CGC   0.85 (+10.14%)
GE   113.12 (+0.12%)
DIS   82.47 (-0.31%)
AMC   7.87 (+2.21%)
PFE   32.57 (-0.85%)
PYPL   58.97 (+0.60%)
NFLX   383.88 (-0.07%)
S&P 500   4,350.02 (+0.46%)
DOW   34,111.68 (+0.12%)
QQQ   360.77 (+0.81%)
AAPL   175.69 (+1.01%)
MSFT   320.05 (+0.16%)
META   304.90 (+3.10%)
GOOGL   131.78 (+1.03%)
AMZN   131.25 (+1.48%)
TSLA   254.40 (-0.51%)
NVDA   417.05 (+1.68%)
NIO   8.65 (+2.37%)
BABA   88.61 (+5.35%)
AMD   97.74 (+1.70%)
T   15.16 (-0.98%)
F   12.63 (+3.52%)
MU   69.22 (+1.94%)
CGC   0.85 (+10.14%)
GE   113.12 (+0.12%)
DIS   82.47 (-0.31%)
AMC   7.87 (+2.21%)
PFE   32.57 (-0.85%)
PYPL   58.97 (+0.60%)
NFLX   383.88 (-0.07%)
NYSE:BTX

Brooklyn ImmunoTherapeutics (BTX) Stock Forecast, Price & News

$2.08
+0.02 (+0.97%)
(As of 09/21/2023 ET)
Compare
Today's Range
$2.00
▼
$2.18
50-Day Range
$2.05
▼
$2.96
52-Week Range
$0.17
▼
$10.10
Volume
4,443 shs
Average Volume
515,543 shs
Market Capitalization
$122.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsHeadlinesOptions ChainSocial Media

BTX stock logo

About Brooklyn ImmunoTherapeutics (NYSE:BTX) Stock

Eterna Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B. The company is headquartered in San Diego, CA.

BTX Price History

BTX Stock News Headlines

September 17, 2023 | americanbankingnews.com
StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)
August 29, 2023 | mirror.co.uk
Brooklyn Beckham's wife Nicola Peltz 'to be grilled on camera' over bitter wedding spat
September 22, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
June 29, 2023 | health.usnews.com
Brooklyn Hospital Center
June 22, 2023 | ft.com
Pure joy: the best of Brooklyn’s cool natural wine scene
June 8, 2023 | forbes.com
Best Moving Companies In Brooklyn, New York June 2023
May 7, 2023 | usnews.com
Brooklyn Technical High School
May 6, 2023 | usnews.com
Brooklyn Preparatory High School
September 22, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
March 31, 2023 | dailymail.co.uk
Brooklyn Beckham: Latest news, views, gossip, photos and video
March 18, 2023 | mirror.co.uk
Billionaire heiress Nicola Peltz and Brooklyn Beckham saving to buy their 'dream house'
March 11, 2023 | mirror.co.uk
Victoria Beckham 'fears for son Brooklyn and his wife Nicola' amid wedding lawsuit
March 1, 2023 | nytimes.com
In Brooklyn, a Tiny Apartment and a Neighborhood Filled With Families
March 1, 2023 | nypost.com
Brooklyn’s priciest rental of 2023 has quickly found a tenant
February 26, 2023 | cbsnews.com
Police ask for help identifying driver at the scene of shooting, carjacking in Brooklyn Park
February 23, 2023 | foxnews.com
Brooklyn Nets sign head coach Jacque Vaughn to multiyear contract extension
February 19, 2023 | nytimes.com
For Strictly Observant Jews in Brooklyn, the Sabbath Expands
February 5, 2023 | yahoo.com
7 Times Brooklyn Beckham Got Roasted for His Questionable Cooking Skills
January 30, 2023 | dailymail.co.uk
Cruz Beckham teaches brother Brooklyn how to cook as he whips up a pizza on family outing in Miami
January 28, 2023 | nypost.com
Like Brooklyn Beckham, I’m a ‘one of the girls’ husband — and I love it
November 12, 2022 | mirror.co.uk
Victoria Beckham ignores Brooklyn and Nicola's anniversary posts as she teases book club
November 4, 2022 | finance.yahoo.com
Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on Form 10-Q
November 4, 2022 | finance.yahoo.com
Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting
November 4, 2022 | finance.yahoo.com
Brooklyn ImmunoTherapeutics Announces Board Changes
November 4, 2022 | finance.yahoo.com
Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
November 4, 2022 | finance.yahoo.com
Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck Cancer
November 4, 2022 | finance.yahoo.com
Brooklyn ImmunoTherapeutics Shares Tick lower After Data From Head and Neck Cancer Study
See More Headlines
Receive BTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brooklyn ImmunoTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Television Broadcasting
Sub-Industry
N/A
Sector
Information
Current Symbol
NYSE:BTX
CUSIP
N/A
CIK
N/A
Web
N/A
Phone
(212) 582-1199
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
58,826,000
Free Float
N/A
Market Cap
$122.36 million
Optionable
Optionable
Beta
4.61
Beginners Guide To Retirement Stocks Cover
Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Matthew Angel
    President, Chief Executive Officer & Director
  • Andrew C. Jackson
    Chief Financial Officer
  • Roger Sidhu
    Chief Medical Officer
  • Jay Sial
    Chief Administrative Officer
  • Sandra Gurrola
    Principal Accounting Officer & VP-Finance

Key Competitors

View All Competitors













BTX Stock - Frequently Asked Questions

How have BTX shares performed in 2023?

Brooklyn ImmunoTherapeutics' stock was trading at $3.22 on January 1st, 2023. Since then, BTX shares have decreased by 35.4% and is now trading at $2.08.
View the best growth stocks for 2023 here.

What is Brooklyn ImmunoTherapeutics' stock symbol?

Brooklyn ImmunoTherapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "BTX."

How do I buy shares of Brooklyn ImmunoTherapeutics?

Shares of BTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Brooklyn ImmunoTherapeutics' stock price today?

One share of BTX stock can currently be purchased for approximately $2.08.

How much money does Brooklyn ImmunoTherapeutics make?

Brooklyn ImmunoTherapeutics (NYSE:BTX) has a market capitalization of $122.36 million.

How can I contact Brooklyn ImmunoTherapeutics?

The company can be reached via phone at (212) 582-1199.

This page (NYSE:BTX) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -